The Japan Times - Fentanyl trade unravels

EUR -
AED 4.049646
AFN 71.675242
ALL 90.778281
AMD 397.56477
ANG 1.974266
AOA 1012.272512
ARS 1704.383265
AUD 1.626896
AWG 1.984848
AZN 1.875207
BAM 1.951638
BBD 2.221563
BDT 137.522844
BGN 1.955594
BHD 0.41713
BIF 3320.234393
BMD 1.102694
BND 1.423744
BOB 12.877364
BRL 6.248188
BSD 1.102948
BTN 104.145446
BWP 15.454815
BYN 3.312532
BYR 21612.793298
BZD 2.223793
CAD 1.573246
CDF 2552.735647
CHF 0.925143
CLF 0.028084
CLP 1105.314352
CNY 7.356895
CNH 7.357501
COP 3660.909457
CRC 495.454355
CUC 1.102694
CUP 26.536267
CVE 110.43488
CZK 24.405929
DJF 196.89134
DKK 7.475551
DOP 67.260955
DZD 151.306138
EGP 58.980864
ERN 16.540403
ETB 181.477338
FJD 2.507911
FKP 0.834617
GBP 0.834204
GEL 2.855792
GGP 0.834617
GHS 12.929079
GIP 0.834617
GMD 81.599127
GNF 9796.051884
GTQ 8.431904
GYD 230.754783
HKD 8.651011
HNL 29.732263
HRK 7.533564
HTG 144.995172
HUF 364.659094
IDR 20108.0577
ILS 3.547032
IMP 0.834617
INR 103.923905
IQD 1676.222214
IRR 2110265.978256
ISK 136.656574
JEP 0.834617
JMD 174.704428
JOD 0.781789
JPY 176.128278
KES 143.405478
KGS 96.414563
KHR 4498.989284
KMF 492.903513
KPW 992.424568
KRW 1472.630658
KWD 0.343456
KYD 0.921387
KZT 492.843542
LAK 24888.753898
LBP 99013.846997
LKR 367.754571
LRD 187.96856
LSL 18.692223
LTL 3.255967
LVL 0.667009
LYD 7.12722
MAD 10.957314
MDL 20.084257
MGA 5023.565053
MKD 61.56418
MMK 2315.959121
MNT 3975.941186
MOP 8.935884
MRU 44.716931
MUR 52.510482
MVR 16.986703
MWK 1917.297319
MXN 20.427723
MYR 4.505717
MZN 70.458957
NAD 18.692223
NGN 1481.546172
NIO 40.692677
NOK 10.53772
NPR 166.632913
NZD 1.994938
OMR 0.424642
PAB 1.102948
PEN 3.762172
PGK 5.045572
PHP 70.528195
PKR 305.748754
PLN 4.405504
PYG 6845.402363
QAR 4.01849
RON 5.35016
RSD 117.501894
RUB 91.310205
RWF 1635.809624
SAR 4.218585
SBD 8.929278
SCR 15.299767
SDG 663.278493
SEK 11.104482
SGD 1.420065
SHP 0.83031
SLE 25.417563
SLL 23122.936136
SOS 631.896863
SRD 41.33971
STD 22823.529858
STN 24.507635
SVC 9.675014
SYP 14337.221722
SZL 18.686822
THB 37.353707
TJS 10.199878
TMT 3.859427
TND 3.317456
TOP 2.655022
TRY 55.544074
TTD 7.505338
TWD 36.26913
TZS 2927.812137
UAH 50.270661
UGX 4555.285975
USD 1.102694
UYU 44.704668
UZS 13296.14231
VES 1006.626048
VND 28367.342551
VUV 132.676188
WST 3.099215
XAF 655.957
XAG 0.022535
XAU 0.000283139053
XCD 2.980084
XCG 1.992721
XDR 0.779662
XOF 655.957
XPF 119.331742
YER 260.841856
ZAR 18.674132
ZMK 9925.561882
ZMW 22.606043
ZWL 355.066869
SSP 6555.933404
MXV 2.294059
  • RYCEF

    0.1000

    19.81

    +0.5%

  • VOD

    -0.2500

    16.33

    -1.53%

  • CMSC

    -0.2800

    20.12

    -1.39%

  • RBGPF

    -2.0000

    65

    -3.08%

  • RIO

    -0.2500

    94.16

    -0.27%

  • BTI

    -1.2000

    54.85

    -2.19%

  • NGG

    -0.3000

    74.94

    -0.4%

  • GSK

    -0.3500

    49.35

    -0.71%

  • BCE

    -0.4200

    20.14

    -2.09%

  • CMSD

    -0.3400

    19.93

    -1.71%

  • BP

    -0.9100

    43.52

    -2.09%

  • RELX

    0.1700

    33.24

    +0.51%

  • BCC

    -0.6200

    75.97

    -0.82%

  • AZN

    -1.9400

    164.21

    -1.18%

  • JRI

    0.0000

    10.77

    0%


Fentanyl trade unravels




Fentanyl, a synthetic opioid up to 50 times more powerful than heroin, has been at the centre of a catastrophic overdose crisis. After years of relentless expansion, the market that once claimed tens of thousands of lives annually is contracting. Preliminary data from the United States Centers for Disease Control and Prevention (CDC) indicate that estimated drug overdose deaths fell to about 80,000 in 2024, a 27 per cent decline from the record of more than 110,000 in 2023, signalling the largest one‑year drop in modern history. This article examines why the fentanyl business is faltering, exploring the interlocking impacts of supply‑chain disruption, international diplomacy, law‑enforcement operations and public‑health initiatives.

From Peak to Downturn
During the early 2020s, illicitly manufactured fentanyl flooded the North American drug market, becoming the leading cause of overdose deaths. The pandemic exacerbated the situation: social isolation and disrupted addiction treatment services contributed to a spike of nearly 110,000 U.S. overdose deaths in 2023. Most of those deaths involved fentanyl, which dealers used to replace or adulterate heroin, counterfeit prescription pills and cocaine. Yet by 2024 the tide had turned. CDC data show that overdose deaths fell by roughly 30,000 in one year, and preliminary numbers for 2025 suggest the decline is continuing. The decrease extends across most U.S. states, with notable reductions in Ohio and West Virginia. Such a sustained downward trend had not been seen in decades and prompted researchers to look beyond domestic policy interventions for an explanation.

Supply‑Chain Disruption and China’s Crackdown
One of the most significant drivers of the decline appears to be a disruption in the global supply of fentanyl and its precursors. Researchers analysing death trends in the United States and Canada found evidence of a sudden shortage of fentanyl on illicit markets beginning in mid‑2023. A Science journal study led by scholars at Stanford and the University of Maryland concluded that Chinese enforcement actions against chemical suppliers have curtailed exports of fentanyl precursors. Officials in Beijing shut down hundreds of companies, removed tens of thousands of online advertisements and arrested about 300 people after agreements with Washington to restrict the trade. The research suggests these moves reduced the availability of 4‑fluoroisobutyryl fentanyl and other precursors, causing the purity of seized fentanyl to fall and the price to rise. According to the DEA’s 2025 National Drug Threat Assessment, some Chinese suppliers have become wary of shipping controlled chemicals, aware that their government is enforcing updated counter‑narcotics treaties. Mexican fentanyl cooks report difficulty obtaining key precursors and are increasingly relying on designer chemicals to circumvent regulations.

Cartel Disruption and Enforcement
While precursor shortages have choked production, targeted law‑enforcement operations have also shaken the industry. White papers from the National Security Data and Policy Institute detail how the capture of Ovidio Guzmán López — a senior Sinaloa Cartel figure and son of Joaquín "El Chapo" Guzmán — in 2023 destabilised the cartel’s synthetic‑drug division. Experts point to a correlation between cartel ‘decapitation’ operations and sharp but temporary declines in fentanyl seizures and overdose deaths. The killing of Nemesio Oseguera Cervantes, leader of the Jalisco New Generation Cartel in late 2025, likewise rattled the market, although researchers caution that rival factions can quickly reconstitute production. The National Drug Threat Assessment notes that the Sinaloa and Jalisco cartels continue to dominate fentanyl production, but they face greater risk as Mexican and U.S. authorities cooperate to target laboratories and intercept shipments at the southwest border. Seizures at border crossings dropped from 29,000 kilograms in 2023 to 23,000 kilograms in 2024, reinforcing evidence of a supply contraction.

Public‑Health Measures and Changing Behaviour
The contraction of the fentanyl trade has amplified the effect of public‑health interventions. Increased distribution of the overdose‑reversal drug naloxone, expansion of medication‑assisted treatment programmes and billions of dollars in opioid settlement funds have collectively improved survival rates. Harm‑reduction services such as supervised consumption sites and drug‑checking kits have proliferated in major cities, allowing users to detect dangerous adulterants like xylazine and medetomidine. Younger Americans appear less likely to initiate opioid use than previous cohorts, and some long‑term users have died or shifted consumption patterns. These behavioural changes mean that a shrinking pool of susceptible individuals is exposed to an increasingly fragmented drug supply.

An Evolving Drug Market
Despite the current downturn, the illicit drug market is far from static. The DEA warns that declining fentanyl purity does not equate to reduced danger. To compensate for shortages, traffickers are mixing fentanyl with veterinary tranquilizers and new synthetic opioids such as nitazenes, which can be even more potent. The National Security Data and Policy Institute notes that precursor chemicals still arrive in Mexico’s Pacific ports such as Manzanillo, and cartels are diversifying sourcing through India and alternative trans‑shipment points. According to the DEA, the presence of xylazine in seized powder has risen steadily since 2020, increasing the risk of fatal respiratory depression and flesh‑rotting wounds. Nitazene analogues and other novel substances are appearing in toxicology reports at an accelerating rate in 2026, underscoring how quickly manufacturers pivot when confronted with enforcement pressure.

The sharp decline in fentanyl‑related deaths offers a glimmer of hope after years of escalating tragedy, but it is not a definitive victory. The current contraction appears to be driven primarily by disruptions in precursor supply, strategic cartel‑targeting operations and strengthened public‑health responses. Yet the same agility that allowed traffickers to flood markets with fentanyl enables them to adapt to enforcement, shifting to new chemicals, routes and business models. Sustained reductions in opioid mortality will require international cooperation to control chemical exports, continued pressure on manufacturing networks, wider access to treatment and harm‑reduction services, and public education to deter drug initiation. As policy makers debate how to allocate resources, the lesson of the fentanyl collapse is clear: comprehensive, co‑ordinated action across borders and disciplines can save lives.